9999999997-18-008382.txt : 20181004 9999999997-18-008382.hdr.sgml : 20181004 20181004150841 ACCESSION NUMBER: 9999999997-18-008382 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20181004 DATE AS OF CHANGE: 20181004 ACTION DATE: 20181004 RECEIVED DATE: 20181004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 181107746 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 CT ORDER 1 filename1.pdf begin 644 filename1 M)5!$1BTQ+C4-)>+CS],-"C0X(# @;V)J#3P\+TQI;F5AF4@-C$O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F#R A(,4X $XWT@P1(&)-CM@<0G(08F1H;](%D&1G3B/^.4/P !!@"U" ;D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @ M(" @#0HV," P(&]B:@T\/"]#(#8Y+T9I;'1E7!E+T]B M:E-T;3X^]W=[9DQ4W2+2]C#Q=+]Z7?G4Z_&,,$,S&3"3.6*0.;A$FM M##,ID[&1[('?3*>3K,E7S$3@?/=X>MDP*%?-I]O0I+]:;EL6QXA_R MSG01"8_ MV5VUR\KW9+O-=CDG"QA(_W5^,:FVJR\+LL_;.F^7&WY;U;ML2ZK[#I$5@M^T MV;987I?K;7"0>=5NF@=K$_8O!4:P8!/1I))A5"H;,TM>M8RD]R"A)R1?7:$NU[GQQ[_Q@;^ .PCQ42)@T"HHR MB?3 ""0$:TCLOJ'>Q_3KI%\[NX\!H%%@(U!] \B>:J:4H*_!K^F;8P(<[@;" MSG4*R.HW&$(EF2$\3.%2=\X^J@>(P-!#]YU4(P!.$*S#8#6:1:,G3+W#L7])OO$^_PIY'OV\RKS["O(DX3;PZ M.4F\YW)N\C]SKA8#?2*CH$TFHZ<FPG?@W@5AZ-\5 MVI+@C3D_C"7*E=+;/#7W<2'CZCCU9$),V[.B9\> @,)WI=P[/O27 KC"GHP9 M5T,_%:X3?(?R(..BWVG&Q>J)<*5\1;B.$5X1;IJP1URKV<+S:.OGWY7@[@[&)P%\%T;29@/5V>78Q& M$2@8/9PI#6%DILU_$4$>]621P6AQ%H 8_7-V]0'7.GVJUJ=Z$"JI4AC-]HCJ M6C0Z)ADWDC**8AA-C47\]@)A+(O"*;@//HH4@B$^;H2&8'1UB>]P)T)E1GT< MC*[NQ)^C=V9CHRI"+;DL>OBVSX*DMH VUK2.7XP%*I%YYIM@]LH@N!*AV6OP M\?9&A+'9E(;\SI]8#/K#2^")/X2*S(I?1)A T!_^+!HM,/B-)C^(L(=/76MB M'?SD&18<=AS<[59:NY7+N!5$H\1L,15&4R6,TM6$M'[&B6=\0'(..E(]VB:3 M>7HH>ED3/:UDG!]+=WX@V*DLTHZAQIK;2P[3+5#,;OLFV2:20S_F'$[@+S:< MPVM1U-^MBM::_J\G[^1^<]C^L.0Y1 \\B<[^<2C#?U51 TE M:9BNR;G")"!B_>>LY88BLZ0%4]F-@%3)H0"HAA;#5.;Z: ::@PSF2:^M]=" ML:WLL[9G$H8(QI4$,BR((E0;*'RF,JJI+<1Q)&/K6Q!G<:Q)DLS@[[&3IUG* M@:ISH-#=^V @0H.-ZY^VXM"@/L[R7NIT;[G8<'I82.UQ3_#7KM\!10TUFY*E MN&2%!B0YPRP^$.5T;P':@;L&#QV\$2L2IWP3*D-V##%#8X1=3+!3*/),&!M3 MO.X1?C2[H?45Z6KASX6T)S,'1-\+XA5C$ 9&TA#5ML)DLR#P&2.4]"28S M&./?DO^>GN:>,.D9,^/;68686L)F.;/$'R.!$L)N,4PJE6E6&[?QX:B3"L:')T/&D89.D5;:F2&8K/ I+?#Q@ ML2]G@LS*[&15CO%]#M4S?J8/-%,M/"$;:=) "I^9&4NGV$Z;MP6O+]W.4%9 MVKXR8=".&_Q26R.5?8<'DH1OY<3>E9KH3 ^ M:&E%"X$L@6O1:YF]@&X[T/,.O':,\)X9PE"4QP [0G]O8SLG^]B/SA9A;)C$ MYWJ#)-1&[5'=2SQYX&3D3CRHZ=1K,@)Y@ 2RDWM)E>\5;4#Z5N3V*# H[=E! M!P@59!W;[Z'9DUVR6^W31(=IS?0 DYHS=(/P':2SAVWTB6QSG&:V,ZNCII9A M[=--RV2Z:5< ,>N2/E8$2#X =E R+(\ H//)CVZHH)YG2 M%^Z"@%/GYC+Q$>7(IFIW_Y;UVW M:+RY]6- H&=+G_AOEZD4E%8NO,K)^S[RC \6%[;#N5SQ.NO< M"IXVDZU:.^?,?Q,Q4L#,=W3J +*RC,%V^G5=@I<$QBN9:#59)[F&HBY=T\TY MD+*O7A1XK\VL]HB^6#TGP8&$2*;&6BNOK&->DQDU%B\NR\4I4+;^UGOI=PO>=N@7=;BPBGC) D,U(<3;E)*!^X,2B==:^V+V#%P0N8 MUTSQ>B[X[!CT VS=A==M74IW'$, MFE#X_5T7<@-B$&XC%UR*Z5%WI]WKA6F(FNM%NRNI^*#:(_S#27GJ"M:Y(4Q: M:6\U8Z]6-YQ:DP5=20U'HB<>#3"7U9<25,V0&7=HW=Z)-A9>;''#L\S0-F8O MD,NL9S/ZBI.DBX,95DV&A3^U@=GRZ:_/_3?&P0<@*FT&Z>O;:X M3ML[KF.RR;RJ,\ YFJT=-%,7YMT>I8[/8I3]$6YU>O'&P3LN"=-GV^_OK5G5 MV/)]:&QS*+(G+Y;Y81\SYZ-"V6-9WG^QV1+MG2ZZOQ)T1>/H=%%UNNCI1R(^ M_4C$^X\$B5Z-SOX38 #9KEET#0IE;F1S=')E86T-96YD;V)J#34S(# @;V)J M#3P\+T9I;'1E+V!-+B@J =('@-@H);4X&4A_ >+,\I(" MH#AC I MDI0-9H/4B62'!#D#V1U -E]):@5(C,$YOZ"R*#,]HT3!T-+24L$Q M)3\I52&XLK@D-;=8P3,O.;^H(+\HL20U!:@6:@<(\+L7)58JN"?FYB8J&.D9 MD>AR(@ H+"&LSR'@,&(4.X\00X#DTJ(R*).1R9B! 2# $G&."\-"F5N9'-T M7!E+T]B:E-T;3X^?I29 M9MN-/>]BAM*O3Q1_*1$L%% 2E$#!0@44*W 60E6",(&%A4<*T[R,N(/4UQI 5F*B(".8_3 /QW9 I X\H;(2ZDB0.9Y MBH",\$4%R+R0US$JQ #(O&BY2.;%X("8%RL/Q+R""B#F%;P?,:]D.#&OC)&/ MPZ58/A;SJH PEU8%(-["*%XH7B9\H/LX*98VI3IXVT8KE_ M?KFW^0IFQ3QTWG7]U$QMWYEZ:#IS/D[MSV8SF96Y:!^>VGX[-L/ND).K;AH/ MYG+7C).Y;K?[,9G/;SS)]K]N-/]J5[:KM4[QKV M[*C^OI_RF)3!/K:_4K^?CNG^X64SML,I'=+X]\":[\1%_YJK-W?=8QI/I,7B M_[1_?DO6?&VZ[8>KY:>[^B-?B./;VD*PQZNQDB?"CTFK1+62U$JO5@:U,JJ5 MA5I9JI65OO/O,$GODM/;Y/0^.;U13N^4TUOE]%XYO5E.[Q;JW<)WO"F]6ZAW M"_5NH=XMU+N%>K=0[Q;JW2*]6Z1WB][Q%ZAWBU1N_19@ #67;.0-"F5N9'-T M7!E+UA- M3"]4>7!E+TUE=&%D871A/CYS=')E86T-"CP_>'!A8VME="!B96=I;CTB[[N_ M(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK8SED(C\^"CQX.GAM<&UE=&$@ M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!# M;W)E(#4N-BUC,#$U(#@T+C$U.3@Q,"P@,C Q-B\P.2\Q,"TP,CHT,3HS," @ M(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z&UL;G,Z>&UP M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X M;6QN&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M M96YT&UP.D-R96%T941A=&4^,C Q."TQ,"TP-%0Q M-3HP-CHU-BTP-#HP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z M365T861A=&%$871E/C(P,3@M,3 M,#14,34Z,#8Z-3&UP.D-R96%T;W)4;V]L/@H@(" @ M(" @(" \>&UP34TZ1&]C=6UE;G1)1#YU=6ED.C-E-#4R-&9B+34P9#4M-&5C M8RTY83,Y+6(T,F$Y9# U83&UP34TZ1&]C=6UE;G1)1#X*(" @(" @ M(" @/'AM<$U-.DEN#I3;W5R8V5-;V1I9FEE9#Y$.C(P,3@Q,# T,3DP-C(V/"]P M9&9X.E-O=7)C94UO9&EF:65D/@H@(" @(" @(" \<&1F>#I#;VUP86YY/E-E M8W5R:71I97,@86YD($5X:&%N9V4@0V]M;6ES#I#;VUP86YY M/@H@(" @(" @(" \<&1F>#I#;VUM96YT#I# M;VUM96YT7!E+T]B:E-T;3X^DZ;48,T(Y,$UG]ONBR+!V_#\+[/3#D#A-6J:&*XLF31Y\6&AX%< M\-F1Q%MVH#[Q=WO7[I$=J(]B@R4/VAGX^KEJ=R$82]:/\105TB%-K0Z4M

PI.88[&A78VDZT/$!5X^,'CM)3-3K<-"F5N M9'-T8;@()1@: M , L]L%9PT*96YD